GALAPAGOS NV/S (NASDAQ:GLPG) Receives $167.89 Average Price Target from Brokerages

GALAPAGOS NV/S (NASDAQ:GLPG) has been assigned a consensus rating of “Buy” from the sixteen analysts that are presently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $179.00.

GLPG has been the subject of several recent analyst reports. Raymond James cut shares of GALAPAGOS NV/S from a “strong-buy” rating to a “market perform” rating in a report on Monday, July 15th. Stifel Nicolaus raised their target price on shares of GALAPAGOS NV/S from $121.00 to $188.00 and gave the stock a “buy” rating in a report on Monday, July 15th. Nomura raised their target price on shares of GALAPAGOS NV/S from $140.00 to $209.00 and gave the stock a “buy” rating in a report on Monday, July 29th. Cowen reiterated a “buy” rating on shares of GALAPAGOS NV/S in a report on Friday, July 26th. Finally, Credit Suisse Group reiterated an “outperform” rating on shares of GALAPAGOS NV/S in a report on Wednesday, July 10th.

Shares of NASDAQ:GLPG traded up $1.09 during trading hours on Friday, hitting $161.16. 98,592 shares of the company’s stock traded hands, compared to its average volume of 111,566. GALAPAGOS NV/S has a 52 week low of $85.00 and a 52 week high of $191.63. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.40 and a current ratio of 6.40. The company’s fifty day simple moving average is $170.20 and its two-hundred day simple moving average is $132.72. The company has a market cap of $8.32 billion, a price-to-earnings ratio of -244.18 and a beta of 1.58.



GALAPAGOS NV/S (NASDAQ:GLPG) last announced its earnings results on Thursday, July 25th. The biotechnology company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.13). GALAPAGOS NV/S had a negative return on equity of 5.45% and a negative net margin of 19.95%. The firm had revenue of $75.96 million during the quarter, compared to analyst estimates of $56.66 million. On average, analysts anticipate that GALAPAGOS NV/S will post 5.17 EPS for the current fiscal year.

Hedge funds have recently bought and sold shares of the stock. Tower Research Capital LLC TRC boosted its holdings in shares of GALAPAGOS NV/S by 170.7% during the second quarter. Tower Research Capital LLC TRC now owns 249 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 157 shares during the period. Royal Bank of Canada boosted its holdings in shares of GALAPAGOS NV/S by 206.1% during the second quarter. Royal Bank of Canada now owns 251 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 169 shares during the period. Ladenburg Thalmann Financial Services Inc. acquired a new stake in shares of GALAPAGOS NV/S during the second quarter worth approximately $59,000. Quantamental Technologies LLC acquired a new stake in shares of GALAPAGOS NV/S during the second quarter worth approximately $74,000. Finally, Shilanski & Associates Inc. acquired a new stake in shares of GALAPAGOS NV/S during the second quarter worth approximately $208,000. Institutional investors and hedge funds own 16.67% of the company’s stock.

GALAPAGOS NV/S Company Profile

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

Featured Article: 52-Week High/Low

Analyst Recommendations for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.